Daniela Fazzotta, Executive MBA, MMD is a seasoned Senior Executive specialized in advanced medicinal technologies. She serves as Chief Strategy Officer at WBP Research Institute in establishment in Basel Switzerland (CH). In her role, she enables decision-making and leads the strategy development function. She is heading high-impact global initiatives supporting the advancement of precision medicine in neuroscience (from basic science to novel technologies, incl. digital biomarkers) with a gender-specific focus.
Besides, over the past two and a half years, Daniela built extensive expertise in the value creation of cell and gene therapies for rare and devastating diseases. She addresses the importance of objective value assessment and promotes accessibility for patients in urgent need. Prior to that, Daniela gained relevant experience in different therapeutic areas, including, hematology, oncology, cardiovascular, immunology, obesity/diabetes, and respiratory.
Daniela studied Pharmaceutical Sciences and Medicines Development with a major in Personalized Medicine/Advanced Technologies: Cell and Gene Therapies at the ECPM Medical Faculty of the University of Basel (CH). In addition, she graduated in Economics/Business Management (4-year academic degree) supplemented by a major in Corporate Finance. She then earned an Executive MBA from the University of Lausanne (CH), and the SDA Bocconi of University Milan, Italy, focusing on Leadership Excellence and Corporate Strategy.